May 7, 2020 / 12:33 PM / 25 days ago

BRIEF-Lipocine Announces Q1 2020 Financial And Operational Results

May 7 (Reuters) - Lipocine Inc:

* LIPOCINE ANNOUNCES FIRST QUARTER 2020 FINANCIAL AND OPERATIONAL RESULTS

* RESUBMITTED NDA FOR TLANDO

* FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION AND ESTABLISHED AUGUST 28, 2020 AS PDUFA GOAL DATE

* RECEIVED FDA CLEARANCE ON IND APPLICATION FOR PHASE 2 CLINICAL STUDY WITH LPCN 1148 FOR TREATMENT OF NASH IN CIRRHOTIC PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below